[go: up one dir, main page]

TNSN01051A1 - DOSAGE FORMS OF CALCIUM CHANNEL BLOCKERS FOR THE TREATMENT OF KIDNEY DISEASE - Google Patents

DOSAGE FORMS OF CALCIUM CHANNEL BLOCKERS FOR THE TREATMENT OF KIDNEY DISEASE

Info

Publication number
TNSN01051A1
TNSN01051A1 TNTNSN01051A TNSN01051A TNSN01051A1 TN SN01051 A1 TNSN01051 A1 TN SN01051A1 TN TNSN01051 A TNTNSN01051 A TN TNSN01051A TN SN01051 A TNSN01051 A TN SN01051A TN SN01051 A1 TNSN01051 A1 TN SN01051A1
Authority
TN
Tunisia
Prior art keywords
dosage forms
calcium channel
treatment
kidney disease
channel blockers
Prior art date
Application number
TNTNSN01051A
Other languages
French (fr)
Inventor
Paul Foster Adrian
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN01051A1 publication Critical patent/TNSN01051A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’INVENTION DECRIT DES FORMES POSOLOGIQUES UNITAIRES D’AGENTS DE BLOCAGE DU CANAL CALCIUM, TELS QUE L’AMLODIPINE. CES FORMES POSOLOGIQUES COMPRENNENT FACULTATIVEMENT UN AGENT ANTI-HYPERTENSEUR D’UNE CATEGORIE DIFFERENTE. APPLICATION : UTILISATION DE CES FORMES POSOLOGIQUES POUR LE BLOCAGE DU CANAL CALCIUM A DES FINS DE TRAITEMENT D'UNE MALADIE RENALE CHEZ DES ANIMAUX NORMOTENSIFS.THE INVENTION DESCRIBES UNIT DOSAGE FORMS OF CALCIUM CHANNEL BLOCKING AGENTS, SUCH AS AMLODIPINE. THESE DOSAGE FORMS OPTIONALLY INCLUDE AN ANTI-HYPERTENSION AGENT OF A DIFFERENT CATEGORY. APPLICATION: USE OF THESE DOSAGE FORMS FOR BLOCKING THE CALCIUM CHANNEL FOR THE TREATMENT OF RENAL DISEASE IN NORMOTENSITIVE ANIMALS.

TNTNSN01051A 2000-04-04 2001-04-03 DOSAGE FORMS OF CALCIUM CHANNEL BLOCKERS FOR THE TREATMENT OF KIDNEY DISEASE TNSN01051A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008332.9A GB0008332D0 (en) 2000-04-04 2000-04-04 Treament

Publications (1)

Publication Number Publication Date
TNSN01051A1 true TNSN01051A1 (en) 2005-11-10

Family

ID=9889228

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01051A TNSN01051A1 (en) 2000-04-04 2001-04-03 DOSAGE FORMS OF CALCIUM CHANNEL BLOCKERS FOR THE TREATMENT OF KIDNEY DISEASE

Country Status (12)

Country Link
EP (1) EP1284719A2 (en)
JP (1) JP2003528927A (en)
AR (1) AR027763A1 (en)
AU (1) AU2001239510A1 (en)
BR (1) BR0109783A (en)
CA (1) CA2403950A1 (en)
GB (1) GB0008332D0 (en)
MX (1) MXPA02009819A (en)
PA (1) PA8514601A1 (en)
PE (1) PE20011163A1 (en)
TN (1) TNSN01051A1 (en)
WO (1) WO2001074390A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT5874U1 (en) * 2000-12-29 2003-01-27 Bioorg Bv PHARMACEUTICAL PREPARATIONS CONTAINING AMLODIPINMALEAT
EP1345901A2 (en) * 2000-12-29 2003-09-24 Bioorganics B.V. Process for making amlodipine, derivatives thereof, and precursors therefor
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
PT1443917E (en) * 2001-11-07 2006-06-30 Synthon Bv TAMSULOSIN TABLETS
NL1019882C2 (en) * 2002-02-01 2003-08-04 Synthon Licensing Pharmaceutical tablet composition useful for treating or preventing hypertension, angina or congestive heart failure comprises amlodipine free base
CO5400144A1 (en) 2002-03-11 2004-05-31 Novartis Ag ORGANIC COMPOUNDS
EP1551456A4 (en) 2002-09-30 2007-08-22 Kowa Co PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING RENAL DISEASES
PL377344A1 (en) 2003-01-31 2006-01-23 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
BRPI0607791A2 (en) 2005-03-15 2010-03-23 Lupin Ltd Amlodipine and benazepril pharmaceutical compositions
BRPI0611024A2 (en) * 2005-04-29 2010-11-09 Hills Pet Nutrition Inc method for extending feline life, for delaying the onset of feline renal failure and for reducing morbidity and mortality from feline kidney disease, kit and means for communicating information or instructions related to the use of a diet having reduced levels of protein, phosphorus and sodium
CN108778334A (en) * 2016-03-24 2018-11-09 第三共株式会社 Drug for treating kidney trouble

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
DK0459666T3 (en) * 1990-05-31 1994-12-05 Pfizer Medicines for impotence
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
EP1013275A3 (en) * 1991-11-26 2001-01-10 Sepracor, Inc. Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
WO1996028185A2 (en) * 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Also Published As

Publication number Publication date
GB0008332D0 (en) 2000-05-24
BR0109783A (en) 2003-01-21
CA2403950A1 (en) 2001-10-11
WO2001074390A2 (en) 2001-10-11
PA8514601A1 (en) 2002-08-26
AU2001239510A1 (en) 2001-10-15
WO2001074390A3 (en) 2002-05-30
AR027763A1 (en) 2003-04-09
PE20011163A1 (en) 2001-11-12
JP2003528927A (en) 2003-09-30
MXPA02009819A (en) 2003-03-27
EP1284719A2 (en) 2003-02-26

Similar Documents

Publication Publication Date Title
TNSN01051A1 (en) DOSAGE FORMS OF CALCIUM CHANNEL BLOCKERS FOR THE TREATMENT OF KIDNEY DISEASE
EP1651195A4 (en) PHARMACEUTICAL METHODS, DOSAGE AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MA25823A1 (en) COMPOSITIONS FOR THE TREATMENT OF WATER.
MA26207A1 (en) WATER TREATMENT COMPOSITIONS.
TNSN01173A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING AN NMDA RECEPTOR ANTAGONIST.
TNSN01053A1 (en) NOVEL COMPOSITIONS COMPRISING A PARTIAL NICOTINE RECEPTOR AGONIST AND AN ANALGESIC AGENT
EP1641748A4 (en) INHIBITORS OF BETA-SECRETASE BASED ON N-ALKYL PHENYLCARBOXAMIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EE200200716A (en) Compounds for the Treatment of Alzheimer's Disease
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
EP1643986A4 (en) PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1638950A4 (en) CYCLOHEXYLGLYCIN DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
DZ3332A1 (en) TREATMENT METHOD USING LIGAND-IMMUNOGENIC CONJUGATES
EP1074268A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENTS FOR INFLAMMATORY BOWEL CONDITIONS CONTAINING IL-6 ANTAGONISTS AS AN ACTIVE INGREDIENT
EP1583750A4 (en) MACROCYCLIC BETA-SECRETASE INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
DK1401501T3 (en) Oral pharmaceutical compositions with modified release of the active ingredient
DK1339407T3 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
MA27509A1 (en) SUSTAINED RELEASE FORMULATIONS CONTAINING LAMOTRIGIN
DK1257292T3 (en) Use of IL-18 Inhibitors
DK1764111T3 (en) Vaginally administered anti-dysrhythmia agents for the treatment of uterine dysrhythmia
HN2001000277A (en) PIRROLO [2,1 - a] DIHYDROISOQUINOLINS
DZ3014A1 (en) Medicines for the treatment of hypertension.
EP1483400A4 (en) USE OF AXL RECEPTOR FOR THE DIAGNOSIS AND TREATMENT OF RENAL DISEASE
MA26899A1 (en) PREPARATIONS CONTAINING A GLUCOCORTICOID MEDICAMENT FOR THE TREATMENT OF BRONCHOPULMONARY DISEASES.
TNSN02038A1 (en) NEW PREGABALIN AND LACTOSE CONJUGATED COMPOUNDS AND COMPOSITIONS CONTAINING THEM
FR2804984B1 (en) SCAFFOLDING SYSTEM FOR VARIOUS SHAPED CAPACITIES